



**ASX Announcement  
Invitrocue Limited (ASX:IVQ)**

**Invitrocue establishes Hong Kong laboratory**  
New lab to support Invitrocue's expansion into the Greater China region

**Highlights**

- Lab in Hong Kong to provide greater access to oncologists and patients in Greater China region of mainland China, Hong Kong and Macau
- Lab will be used for R&D and commercial purposes
- Lab is currently being equipped and will be completed and operational by November 2019
- Hired key staff for the lab including a General Manager

27 September 2019: **Invitrocue Limited (ASX: IVQ) ('Invitrocue' or 'the Company')**, an Innovative life sciences company, is pleased to announce that the establishment of laboratory facility in Hong Kong.

The Hong Kong facility, which will be used for research and development and for commercial purposes, provides Invitrocue with better access to the network of supportive early adopters of its unique Onco-PDO™ technology in the region. This includes primarily oncologists and hospital groups based in Hong Kong and also opportunities in mainland China and Macau.

The potential demand from these markets is substantial. Hong Kong had 31,468 new cancer cases in 2016, with colorectum, breast and lung cancer being the three leading cancers. (Hong Kong Cancer Registry, Hospital Authority 2018) Cancer is the leading cause of death in China, with 4.3 million new cancer cases in 2018. Cancer incidence rates in China are expected to grow to 6.7 million by 2040. (Globocan 2018)

**Laboratory to be operational in Q4**

Invitrocue received access to the laboratory space in June 2019 and is in the process of equipping the facility. The laboratory is located at the Hong Kong Science and Technology Park, a vibrant regional hub for innovation and technology development.

Invitrocue has already hired key staff for the laboratory including a General Manager, an R&D leader/manager and a Clinical Coordinator. The Company expects the laboratory to be completed and operational by November 2019.

**Dr Steven Fang, Executive Chairman of Invitrocue, said:** "We are excited to now have a laboratory in Hong Kong. This new facility will not only make it easier to work with early Hong Kong-based adopters of our unique cancer diagnostic technology, such as oncologists and hospitals, but also gives us access to the enormous Greater China region. The new lab is an important milestone in the international expansion of our capability to help cancer patients receive the right drug at the right time. "

**Ends**



**For further information, please contact:**

**Invitrocue**

**Martin D. Bach**

VP Operations

M: +65 6460 0497

E: [martind.bach@invitrocue.com](mailto:martind.bach@invitrocue.com)

**Media & investor enquiries**

**Julia Maguire**

The Capital Network

M: +61 419 815 386

E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**[www.invitrocue.com](http://www.invitrocue.com)**

**About Invitrocue (ASX:IVQ)**

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A\*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators. Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ.

To learn more, please visit: [www.invitrocue.com](http://www.invitrocue.com)